170 related articles for article (PubMed ID: 18398161)
1. Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer.
Punt CJ; Koopman M
J Clin Oncol; 2008 Apr; 26(11):1907-8; author reply 1908-9. PubMed ID: 18398161
[No Abstract] [Full Text] [Related]
2. Dose-modified XELIRI chemotherapy for metastatic colorectal cancer--a retrospective study of 78 patients.
Tarver K; Conibear J; Raouf S
Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):453-4. PubMed ID: 22472457
[No Abstract] [Full Text] [Related]
3. [Capecitabine and irinotecan].
Gasperoni S
Suppl Tumori; 2004; 3(4):S107-8. PubMed ID: 15206231
[No Abstract] [Full Text] [Related]
4. Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
Montagnani F; Chiriatti A; Licitra S; Aliberti C; Fiorentini G
Clin Colorectal Cancer; 2010 Oct; 9(4):243-7. PubMed ID: 20920997
[TBL] [Abstract][Full Text] [Related]
5. Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
Cartwright T; McCollum D; Boehm KA
Am J Clin Oncol; 2010 Jun; 33(3):307-13. PubMed ID: 20375835
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer.
Gennatas C; Michalaki V; Gennatas S; Papalambros E
Anticancer Res; 2008; 28(3B):1923-6. PubMed ID: 18630482
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Köhne CH; De Greve J; Hartmann JT; Lang I; Vergauwe P; Becker K; Braumann D; Joosens E; Müller L; Janssens J; Bokemeyer C; Reimer P; Link H; Späth-Schwalbe E; Wilke HJ; Bleiberg H; Van Den Brande J; Debois M; Bethe U; Van Cutsem E
Ann Oncol; 2008 May; 19(5):920-6. PubMed ID: 18065406
[TBL] [Abstract][Full Text] [Related]
8. Strategic options on behalf of patients with metastatic colorectal cancer: mass tumor murder versus serial tumor killing.
Goldberg RM
Onkologie; 2010; 33(6):291-2. PubMed ID: 20523091
[No Abstract] [Full Text] [Related]
9. A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
Kim KP; Kim HS; Sym SJ; Bae KS; Hong YS; Chang HM; Lee JL; Kang YK; Lee JS; Shin JG; Kim TW
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1609-17. PubMed ID: 23595344
[TBL] [Abstract][Full Text] [Related]
10. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.
Fuchs CS; Marshall J; Barrueco J
J Clin Oncol; 2008 Feb; 26(4):689-90. PubMed ID: 18235136
[No Abstract] [Full Text] [Related]
11. First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer.
Park SH; Bang SM; Cho EK; Baek JH; Oh JH; Im SA; Park YS; Shin DB; Lee JH
Oncology; 2004; 66(5):353-7. PubMed ID: 15331921
[TBL] [Abstract][Full Text] [Related]
12. Update on capecitabine alone and in combination regimens in colorectal cancer patients.
Silvestris N; Maiello E; De Vita F; Cinieri S; Santini D; Russo A; Tommasi S; Azzariti A; Numico G; Pisconti S; Petriella D; Lorusso V; Millaku A; Colucci G
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S46-55. PubMed ID: 21129610
[TBL] [Abstract][Full Text] [Related]
13. Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications.
Dahan L; Ciccolini J; Evrard A; Mbatchi L; Tibbitts J; Ries P; Norguet E; Mercier C; Iliadis A; Ouafik L; Lacarelle B; Seitz JF
J Clin Oncol; 2012 Feb; 30(4):e41-4. PubMed ID: 22184401
[No Abstract] [Full Text] [Related]
14. Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?
Schmoll HJ; Sargent D
Lancet; 2007 Jul; 370(9582):105-107. PubMed ID: 17630019
[No Abstract] [Full Text] [Related]
15. Capecitabine in combination with irinotecan or oxaliplatin in advanced colorectal cancer.
Clin Colorectal Cancer; 2003 Aug; 3(2):89-91. PubMed ID: 12952563
[No Abstract] [Full Text] [Related]
16. Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer.
Vincenzi B; Schiavon G; Pantano F; Santini D; Tonini G
Nat Clin Pract Oncol; 2008 Aug; 5(8):455-65. PubMed ID: 18542119
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomised phase II study.
Price TJ; Townsend AR; Khattak A
Ann Oncol; 2010 Oct; 21(10):2121; author reply 2121-2. PubMed ID: 20860991
[No Abstract] [Full Text] [Related]
18. Metastatic colorectal cancer: is surgery necessary?
Schmidt C
J Natl Cancer Inst; 2009 Aug; 101(16):1113-5. PubMed ID: 19671774
[No Abstract] [Full Text] [Related]
19. Capecitabine combinations in the treatment of advanced colorectal cancer.
Fisher MD
Clin Colorectal Cancer; 2001 Nov; 1(3):146-8. PubMed ID: 12450426
[No Abstract] [Full Text] [Related]
20. Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study.
Gunnlaugsson A; Anderson H; Fernebro E; Kjellén E; Byström P; Berglund K; Ekelund M; Påhlman L; Holm T; Glimelius B; Johnsson A
Eur J Cancer; 2009 Mar; 45(5):807-13. PubMed ID: 19110416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
